公开(公告)号：US20140128580A1

公开(公告)日：2014-05-08

申请号：US14149979

申请日：2014-01-08

Applicant: Genentech, Inc.

Inventor： Allen J. Ebens, JR. ,  Frederic S. Jacobson ,  Paul Polakis ,  Ralph H. Schwall ,  Mark X. Sliwkowski ,  Susan D. Spencer

IPC: A61K47/48

CPC classification number: A61K47/6803 ,  A61K47/6875 ,  A61K2039/505 ,  C07D498/18 ,  C07K16/1063 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/3046 ,  C07K16/3069 ,  C07K16/32 ,  C07K2317/24

Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p  I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.

Abstract translation: 本发明涉及式I的抗体 - 药物偶联化合物：Ab-（LD）p I，其中一种或多种美登木素生物碱药物部分（D）通过L共价连接到结合ErbB受体的抗体（Ab），或 其结合一种或多种肿瘤相关抗原或细胞表面受体。 这些化合物可用于诊断或治疗癌症及其它疾病和病症的方法中。

公开(公告)号：US10556966B2

公开(公告)日：2020-02-11

申请号：US16170819

申请日：2018-10-25

Applicant: Genentech, Inc.

Inventor： Xiaocheng Chen ,  Mark Dennis ,  Jagath Reddy Junutula ,  Gail Lewis Phillips ,  Thomas Harden Pillow ,  Mark X. Sliwkowski

IPC: C07K16/32 ,  A61K47/68 ,  A61K39/395 ,  C07K16/28 ,  G01N33/574 ,  A61K31/5517 ,  A61K31/675 ,  A61K31/704 ,  A61K49/00 ,  C07K16/30

Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.

公开(公告)号：US09963517B2

公开(公告)日：2018-05-08

申请号：US14946318

申请日：2015-11-19

Applicant: Genentech, Inc. ,  University of Turku

Inventor： Mark X. Sliwkowski ,  Klaus Elenius ,  Maija Hollmen

IPC: A61K6/00 ,  A61K39/00 ,  C07K16/40 ,  C07K16/32 ,  G01N33/574

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/30 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57492 ,  G01N2333/71

Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.

公开(公告)号：US20170274092A1

公开(公告)日：2017-09-28

申请号：US15438418

申请日：2017-02-21

Applicant: GENENTECH, INC.

Inventor： Xiaocheng Chen ,  Mark Dennis ,  Jagath Reddy Junutula ,  Gail Lewis Phillips ,  Thomas Harden Pillow ,  Mark X. Sliwkowski

IPC: A61K47/48 ,  C07K16/00 ,  A61K39/395 ,  C07K16/32 ,  A61K31/5517 ,  C07K19/00 ,  C07D487/16

CPC classification number: A61K31/5517 ,  A61K39/39558 ,  A61K47/6803 ,  A61K47/6855 ,  A61K47/6869 ,  C07K16/005 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/92

Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.

公开(公告)号：US20140140993A1

公开(公告)日：2014-05-22

申请号：US14166519

申请日：2014-01-28

Applicant: Genentech, Inc.

Inventor： Leanne Berry Ross ,  Gail Lewis Phillips ,  Mark X. Sliwkowski

IPC: A61K47/48 ,  G01N33/50 ,  A61K31/517 ,  A61K31/337 ,  A61K39/395 ,  A61K31/5377

Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract translation: 抗体 - 药物偶联物曲妥珠单抗-MC-DM1和化学治疗剂（包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和药学上可接受的盐）的组合可用于抑制肿瘤细胞生长，以及用于治疗诸如由 HER2和KDR（VEGFR受体1）。 公开了将这些组合用于体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理条件中的这种疾病的方法。

公开(公告)号：US20140056899A1

公开(公告)日：2014-02-27

申请号：US14066258

申请日：2013-10-29

Applicant: GENENTECH, INC.

Inventor： Germaine Fuh ,  Lauric Haber ,  Gabriele Schaefer ,  Mark X. Sliwkowski

IPC: C07K16/28

CPC classification number: A61K47/48569 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92

Abstract: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.

Abstract translation: 本发明提供抗HER抗体，包括多特异性抗HER抗体，组合物和使用这些抗体的方法。 本文还提供了比传统EGFR拮抗剂毒性小的EGFR / HER3多特异性抗体。